What it is
VK2735 is an investigational peptide that switches on two incretin receptors at once — GLP-1 and GIP — and it has no approved use anywhere. Its developer, Viking Therapeutics, is testing it for weight management. The one peer-reviewed efficacy paper (Bays 2026, Obesity, written by trial investigators with Viking authors) describes it as a GLP-1/GIP receptor dual agonist and says the peptide "incorporates the activities of both incretins and contains a side chain that imparts an extended half-life" when injected under the skin.
| Property | Value | Source |
|---|---|---|
| Class | GLP-1/GIP receptor dual agonist peptide | VENTURE paper |
| Amino-acid sequence | Not published in the sources opened | PubChem: no record (2026-11-20) |
| Half-life feature | A side chain that extends half-life | VENTURE paper |
| Forms in trials | Weekly subcutaneous; once-daily oral | ClinicalTrials.gov |
| Status | Investigational, phase 3 | ClinicalTrials.gov |
How it acts. GLP-1 and GIP are hormones released by the gut after eating that raise insulin and, in the case of GLP-1, slow the stomach and reduce appetite; the library's GLP-1 and GIP entries explain each. The approved drug with the same GLP-1/GIP pairing is tirzepatide, which the VENTURE paper cites as its reference point. Other trial-stage incretin peptides in the library take different pairings — retatrutide adds the glucagon receptor, and survodutide and mazdutide pair GLP-1 with glucagon.
What the human evidence amounts to: one published phase 2 trial lasting 13 weeks, in adults without diabetes, sponsored by the developer. There is no published phase 3 result, no long-term data and no independent pharmacology paper in PubMed.
What the trial showed
VENTURE (NCT06068946) was a phase 2, randomised, double-blind, placebo-controlled dose-finding study run between August 2023 and February 2024. It enrolled adults with obesity, or overweight with at least one weight-related condition; people with diabetes were not eligible. The primary end point was percentage weight change at week 13.
| Weekly dose | Mean weight change at week 13 | Source |
|---|---|---|
| Placebo | −1.8 kg (−1.7%) | PMID 41508550 |
| 2.5 mg (lowest) | −9.2 kg (−9.1%) | PMID 41508550 |
| 15 mg (highest) | −14.6 kg (−14.7%) | PMID 41508550 |
Across all active doses, 93% (130 of 140) lost at least 5% of their starting weight, against 12% (4 of 34) on placebo.
Tolerability, from the full text. Drug-related nausea was reported by 64 of 175 treated participants and vomiting by 22 of 175 — 36.6% and 12.6% by this entry's arithmetic. Of 176 participants, 24 (14%) stopped treatment early, 15 (8.5%) of them because of adverse events. The paper reports that gastrointestinal effects became less frequent after dose titration reached steady state, and lists 12 serious adverse events in 8 participants, of which 2, in the same participant, were judged possibly or probably related (atrial fibrillation and dehydration). One death, from head trauma after a fall, was judged unrelated.
What 13 weeks cannot show: where weight loss levels off, whether it is kept, and how the drug compares with approved treatments. The trials designed to answer the first two are the 78-week phase 3 studies below.
Where it stands
No regulator has approved VK2735; Drugs@FDA and openFDA held no record of it on 2026-11-20. ClinicalTrials.gov listed eight studies that day:
| Trial | Phase | Form | Planned size | Status |
|---|---|---|---|---|
| NCT05203237 | 1 | — | 92 | Completed |
| NCT06068946 (VENTURE) | 2 | Weekly injection | 176 | Completed |
| NCT06828055 (VENTURE-Oral) | 2 | Daily tablet | 280 | Completed (primary completion 2025-06-24) |
| NCT07104500 | 3 | Weekly injection, 78 weeks, no diabetes | 4,500 | Active, not recruiting |
| NCT07104383 | 3 | Weekly injection, type 2 diabetes | 1,100 | Active, not recruiting |
| NCT07868835 (SUNRISE 1) | 3 | Daily tablet | 560 | Recruiting |
| NCT07868939 | 3 | Daily tablet, type 2 diabetes | 560 | Recruiting |
| NCT07838740 | 1 | — | 270 | Recruiting |
The oral phase 2 trial is listed as completed, but this entry found no peer-reviewed results for it in PubMed and does not report figures from it. Weight-loss medicines that are approved, and the question of which suits whom, are covered by GLP-1 Ledger; this library describes the compound.
Sources opened 2026-11-20: Bays 2026, Obesity (VENTURE, PMID 41508550, abstract; full text PMC12933218 for the mechanism description, discontinuations and adverse events); ClinicalTrials.gov API v2 (8 VK2735 studies; NCT06828055 and NCT07104500 records); PubMed E-utilities (2 records); PubChem name search (no record); openFDA and Drugs@FDA (no record).
